Research to Remission Grant
The Research to Remission Grant is designed to provide funding for research that may lead to a significant change in the understanding, diagnosis, and/or treatment of multiple myeloma. Each year, CMRG, with the support of its partners, provides funding for myeloma research. We welcome applicants who hold a Ph.D., M.D., D.V.M, or equivalent and have a demonstrated research environment suitable for their proposed study. For 2021, CMRG will be accepting applications for Real-World Evidence Research using the CMRG Database.
Supported by a research grant from Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.
2021 Grant Important Dates
|Call for proposals||December 3, 2021|
|Submission of study concept||December 30, 2021|
|Review panel meeting||January 19, 2022|
|Notification of Awards||January 24, 2022|
|Award start date||January 31, 2022|